Get the Stockscreener App
5.65
3.91%
-0.23
After Hours:
5.65
Lixte Biotechnology Holdings Inc stock is traded at $5.65, with a volume of 145.38K.
It is down -3.91% in the last 24 hours and up +52.29% over the past month.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
See More
Previous Close:
$5.88
Open:
$5.88
24h Volume:
145.38K
Relative Volume:
2.70
Market Cap:
$69.96M
Revenue:
-
Net Income/Loss:
$-6.01M
P/E Ratio:
-4.5857
EPS:
-1.2321
Net Cash Flow:
$-5.71M
1W Performance:
+7.21%
1M Performance:
+52.29%
6M Performance:
+34.20%
1Y Performance:
+328.03%
1-Day Range:
$5.48
$6.05
1-Week Range:
$5.15
$6.1144
52-Week Range:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
433 PLAZA REAL, BOCA RATON
Compare LIXT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
5.65 | 72.81M | 0 | -6.01M | -5.71M | -1.2321 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
Number of shareholders of Lixte Biotechnology Holdings, Inc. – GETTEX:8640 - TradingView
Lixte Biotechnology Holdings Inc. (LIXT) Q4 2024 Earnings: Net Loss of $0.27 Per Share as Pipeline Progress ContinuesPre-Earnings Drift - Newser
Lixte Biotechnology (LIXT) Holds Near Support After Slight DeclineTrending Volume Leaders - Newser
Lixte Biotechnology (LIXT) Slides 5.25% as Stock Tests Key Support at $5.32Inside Day Breakout - Newser
Why Is Lixte Biotechnology Holdings, Inc. (LIXT) Stock Down Today? - Meyka
According to a filing submitted to the U.S. Securities and Exchange Commission, Glimpse Group Inc has announced its future strategic direction. - Bitget
Since the beginning of this year, STRC has increasingly become the main driver behind Strategy Company's Bitcoin acquisitions. - Bitget
Report: US Gold Corp Hires Mining Veteran Walker for Venezuela Project - Bitget
Lixte Biotechnology Holdings Inc. has officially submitted its 10-Q quarterly report to the U.S. Securities and Exchange Commission for the period ending Q1 2026. - Bitget
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update - The Manila Times
LIXTE Biotechnology Holdings, Inc. Files Q1 2026 10-Q Report, Highlights Progress in Cancer Treatment Development - Quiver Quantitative
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 1Q 2026: Net loss $1.94M, EPS $(0.18) — 10-Q Summary - TradingView
Lixte (NASDAQ: LIXT) Q1 2026 loss deepens amid going-concern risks - Stock Titan
Inside LIXTE’s push on ovarian cancer and proton therapy - Stock Titan
TradingKey - TradingKey
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
LIXT SEC FilingsLixte Biotechnology Hldgs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lixte Biotechnology Holdings, Inc. (LIXT) Latest Stock News & Headlines - Yahoo Finance
LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment - NewMediaWire
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment - TipRanks
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100 - citybuzz -
LIXT Lixte posts Q4 2024 negative EPS of 27 cents and zero revenue, with shares unchanged today.EBITDA Margin - Cổng thông tin điện tử tỉnh Tây Ninh
LIXT Lixte Biotechnology Holdings Inc. shares gain 6.87 percent on positive investor reaction to Q4 2024 earnings release.Professional Trade Ideas - Xã Thanh Hà
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape - The Globe and Mail
Lixte (LIXT) Stock Volume Stability (Bearish Sentiment) 2026-04-20Crowd Entry Signals - Cổng thông tin điện tử tỉnh Lào Cai
LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape - NewMediaWire
Why Cardio Diagnostics Holdings (NASDAQ: CDIO) Is ‘One to Watch’ - Financial-News.co.uk
Lixte Biotechnology stock (US53833K1060): Is its PP2A cancer focus strong enough to unlock breakthro - AD HOC NEWS
Lixte Biotechnology Holdings, Inc. Files Form 8-K with SEC Detailing Restricted Share Unit Awards and Company Information (April 2026) - Minichart
Lixte Biotechnology Updates Executive Equity Compensation With RSUs - The Globe and Mail
Lixte Biotechnology Holdings, Inc. (LIXTW) - Minichart
Lixte Biotechnology Holdings cancels options, grants RSUs to executives and directors - Investing.com India
LIXTE Biotechnology’s LB-100 Represents Novel Approach to Enhancing Cancer Therapies - citybuzz -
Lixte Biotechnology Holdings cancels options, grants RSUs to executives and directors By Investing.com - Investing.com South Africa
Lixte Biotechnology (LIXT) CEO cancels 350K options for shares - Stock Titan
Lixte (LIXT) CFO cancels 50K options, receives 50K RSUs - Stock Titan
LIXTE (LIXT) director cancels 25K options and receives 25K RSUs - Stock Titan
LIXTE (LIXT) director cancels 25K options, receives 25K RSUs vesting immediately - Stock Titan
Lixte (LIXT) cancels insider stock options and grants fully vested RSUs - Stock Titan
Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built - The Globe and Mail
"NextEpochMarket company news.lhl"Results on X | Live Posts & Updates - x.com
LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - USA Today
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - NewMediaWire
Options Flow: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity Warrant2026 Macro Impact & AI Forecast Swing Trade Picks - baoquankhu1.vn
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):